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2Experiment

SUMMARY

Gambogic acid (GA) is a natural compound derived
from Chinese herbs that has been approved by the
Chinese Food and Drug Administration for clinical
trials in cancer patients; however, its molecular
targets have not been thoroughly studied. Here, we
report that GA inhibits tumor proteasome activity,
with potency comparable to bortezomib but much
less toxicity. First, GA acts as a prodrug and only
gains proteasome-inhibitory function after being
metabolized by intracellular CYP2E1. Second, GAinduced proteasome inhibition is a prerequisite for
its cytotoxicity and anticancer effect without offtargets. Finally, because expression of the CYP2E1
gene is very high in tumor tissues but low in many
normal tissues, GA could therefore produce tissuespecific proteasome inhibition and tumor-specific
toxicity, with clinical significance for designing novel
strategies for cancer treatment.

INTRODUCTION
Gambogic acid (GA) is the principal pigment of gamboge resin of
several Garcinia species. The gamboge resin has been used as
a coloring material and traditional Chinese medicine for the
treatment of human diseases (Gruenwald and Jaenicke, 2000).
Recent studies have demonstrated that GA has anticancer
effects and inhibits the growth of multiple types of human cancer
cells in vitro and in vivo (Zhang et al., 2004; Pandey et al., 2007; Yi
et al., 2008). GA has been approved by the Chinese Food and
Drug Administration for the treatment of different cancers in clinical trials (Zhou and Wan, 2007).

In both animal tumor models and clinical trials, GA efficiently
inhibits tumor growth with minimal side effects, with little toxicity
on immune and hemopoietic systems (Guo et al., 2003; Zhou
and Wan, 2007). Thus, identification of the specific molecular
targets responsible for GA-mediated anticancer effect should
have great clinical significance. Some potential molecular targets
of GA have been reported that may contribute to its cytotoxicity
and anticancer activity, including binding to the transferrin receptor and suppressing nuclear factor-kB (NF-kB) signaling pathway
(Pandey et al., 2007) and inhibiting VEGFR2 (Yi et al., 2008).
Intracellular P450 is mainly responsible for the metabolism
of GA (Liu et al., 2006). The metabolites of GA have been well
studied in vivo and in vitro. In rat liver microsomes, GA is rapidly
metabolized to two phase I metabolites, MT1 and MT2 (Liu et al.,
2006). MT1 and MT2 are probably the epoxide metabolite and
hydration metabolite of GA, respectively. Other phase II metabolites of GA were also identified in rat bile, such as 9,10-epoxygambogic acid-30-O-glucuronide and 10-hydroxylgambogic
acid-30-O-glucuronide (Feng et al., 2007). Recently two sulfonic
acid metabolites of GA, 10-a sulfonic acid and 10-b sulfonic acid,
were also found present abundantly in the fecal samples of rats
after intravenous administration (Yang et al., 2011). However, the
major circulating metabolite of GA in humans was identified to be
MT2 (Yang et al., 2010).
Bortezomib (Velcade, Vel) as the first proteasome inhibitor
anticancer drug has been approved by US FDA for the treatment
of multiple myeloma. However, relapses and toxicities were
found to be associated with Vel treatment (Adams, 2004; Richardson et al., 2005), suggesting the need for discovery of novel
proteasome inhibitors with no or low toxicity.
The current study reports the following findings: (1) proteasome is a specific molecular target of GA and GA at a therapeutic dose exerts anticancer effect through proteasome
inhibition without off-targets; (2) GA is a proteasome inhibitor
prodrug that is metabolized to an active proteasome inhibitor
by CYP2E1; (3) due to the selective distribution of CYP2E1, GA
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induces tissue-specific proteasome inhibition and cytotoxicity,
an advantage over other proteasome inhibitors including Vel.
RESULTS
GA Indirectly Inhibits Proteasome Activities
Most recently, we have reported that the combination of GA with
the classic proteasome inhibitor MG132 or MG262 synergistically inhibited tumor cell growth and induced cell death (Huang
et al., 2011a). To elucidate the involved molecular mechanism,
we measured the levels of the proteasome inhibition in human
leukemia K562 cells after treatment with GA alone, MG132 or
MG262 alone, or their combinations. As expected, MG132 or
MG262 treatment alone inhibited proteasomal activity in K562
cells, as measured by increased levels of ubiquitinated proteins
(Figure 1A, lanes 3 and 5). Surprisingly, GA alone was also able to
accumulate the ubiquitinated proteins (Figure 1A, lane 2), which
was dose dependent (Figure 1B). Most importantly, the combination of GA+MG132 or GA+MG262 resulted in higher levels of
ubiquitinated proteins and greater proteasome inhibition than
each treatment alone (Figure 1A, lanes 4 and 6).
To further study the proteasome-inhibitory effect of GA, we
transfected SH-SY5Y cells with a GFPu plasmid, a surrogate
proteasome substrate. We found that GA treatment caused
accumulation of both GFP and ubiquitinated proteins dose
dependently (Figure 1C), confirming that GA is able to inhibit
the cellular proteasome activity.
To determine whether GA is a direct proteasome inhibitor, an
in vitro peptidase assay using an AMC fluorescence proteasome
substrate was performed. GA at up to 5 mM failed to inhibit the
chymotrypsin (CT)-like activity of the purified 20S proteasome
(Figure 1D). Only at 10–50 mM doses, GA exhibited a partial inhibition (IC50 25 mM, Figure 1D). These results demonstrated that
GA itself is not a potent proteasome inhibitor. Consistently, the
computational modeling studies predict that the GA metabolite
MT1, but not GA and MT2, has the potential to interact with
and inhibit the proteasomal b5 chymotryptic subunit (Figure S1;
see Extended Results).
MT1 and CYP2E1 Are Responsible for GA-Induced
Proteasome Inhibition in Tumor Cells
To provide experimental evidence for MT1 as a direct proteasome inhibitor, MT1 was chemically synthesized and purified,
and its effect on the CT-like activity of purified 20S proteasome
was determined. As shown in Figure 2A, MT1 inhibited the purified 20S proteasomal CT-like activity with IC50 value of 0.5 mM,
while in a sharp contrast, GA was inactive at up to 2.5 mM (IC50
25 mM, Figure 1D).
We then determined which isotype of CYP enzymes is responsible for metabolizing GA to MT1 and whether inhibition of this
CYP enzyme could mitigate GA-induced proteasome inhibition
by using a cell-based peptidase assay. We tested inhibitors of
various CYP enzymes for their effects on GA-induced decrease
in proteasome activities. We found that the inhibitors of CYP2D6
(Quinidine/Qui), CYP2C9 (sulfaphenazole/Sul), and CYP3A4 (ketoconazole/Ket) did not alter GA-induced proteasome inhibition
in K562 cells (Figure 2B). However, diethyldithiocarbamate
(DDC), a CYP2E1 inhibitor, dramatically rescued GA-induced
212 Cell Reports 3, 211–222, January 31, 2013 ª2013 The Authors

Figure 1. GA Indirectly Inhibits Proteasome Function
(A) GA enhanced ubiquitinated protein accumulation by MG132 and MG262 in
human leukemic K562 cancer cells. K562 cells were treated with GA (0.5 mM)
for 12 hr in the absence or presence of proteasome inhibitors (MG132: 0.5 mM;
MG262: 0.025 mM), followed by western blotting for total protein ubiquitination.
GAPDH was used as a loading control. The western images were representatives from at least three independent experiments.
(B) GA dose dependently accumulated ubiquitinated proteins in K562 cells.
K562 cells were exposed to either DMSO (DM) or GA for 12 hr, and ubiquitinated proteins and GAPDH were assayed as described in (A).
(C) GA induced the accumulation of GFPu and ubiquitinated proteins in GFPu5Y cells. GFPu-5Y cells were treated with GA as indicated for 9 hr, and GFP
expression was detected by an inverted epifluorescence microscope or
western blotting.
(D) GA at 5 mM or lower doses had no effect on 20S proteasome peptidase
activities. Purified 20S proteasomes were treated with GA at the indicated
doses in a Tris reaction system (pH 7.4). The CT-like peptidase activity was
measured using specific synthetic fluorogenic substrates. Mean ± SD (n = 3).
See also Figures S1 and S2.

proteasome inhibition (Figure 2B), suggesting that CYP2E1
may be responsible for metabolizing GA into MT1. Indeed,
DDC rescued GA-induced proteasome inhibition in K562 cells
in a dose-dependent manner (Figure 2D), and such rescuing
ability could be neutralized by increased concentrations of GA
(Figure 2C). We have also noticed that GA only slightly inhibits
the proteasomal caspase-like activity and dose not have any
effect on the proteasomal trypsin-like activity (Figure S2), indicating that GA (or MT1) selectively inhibits cellular proteasomal
CT-like activity. Furthermore, DDC was also able to suppress
GA-induced proteasome inhibition in Jurkat T, P388, and
HepG2 cells (Figures 2E and 2F; Figure S3).
To further validate the involvement of CYP2E1, we used
small interfering RNA (siRNA) technology to silence intracellular
CYP2E1, which should mimic the effect of its inhibitor DDC.
siRNAs 1 and 2, but not 3 after transfection for 48 hr (Figure 2G)

Figure 2. MT1 Directly Inhibits Proteasome
Peptidase Activity and DDC or CYP2E1
siRNA Partially Disrupts GA-Mediated Proteasome Inhibition
(A) MT1 dose dependently inhibited 20S CT-like
activity. 20S proteasome was treated with different
doses of MT1 and GA, and CT-like activity was
detected as in Figure 1D. Mean ± SD (n = 3).
(B) The effects of P450 inhibitors on CT-like
activities in cultured cells. K562 cells were
exposed to P450 inhibitors (DDC, Ket, Qui, and
Sul) for 6 hr, and then cell-based CT-like activity
was detected. Mean ± SD (n = 3).
(C) DDC partially reversed CT-like activity
decrease induced by GA. K562 cells were incubated with GA in the presence of DDC (100 mM) for
6 hr, and CT-like activities are shown. Mean ± SD
(n = 3).
(D) DDC reversed GA-induced proteasome inhibition in a dose-dependent manner. K562 cells
were treated with various doses of DDC in the
presence of GA (1 mM) for 6 hr, and CT-like activity
was assayed. Mean ± SD (n = 3).
(E and F) DDC (100 mM) partially reversed
GA-induced proteasome inhibition in Jurkat and
P388 cancer cells. As treated in (C), Jurkat cells
and P388 cells were used for CT-like activity
assay. Vel was used as a positive control. Mean ±
SD (n = 3).
(G and H) CYP2E1 siRNA partially silenced
CYP2E1 expression and reversed proteasome
inhibition. HepG2 cells were transfected with
three CYP2E1-siRNA by using lipofectine 2000
agent for 48 hr, and western blotting was
performed to detect the CYP2E1 protein level
(#1 and #2 were effective, G, upper). At 48 hr
transfection time point, various doses of GA
were added, and CT-like activity was assessed after 6 hr treatment (G, lower). As in (G), HepG2 cells were transfected with CYP2E1-siRNA (#2) for 72 hr,
and CYP2E1 (upper) and CT-like activity (lower) were detected (H). Mean ± SD (n = 3).
(I) CYP2E1 and CYP1A2 protein distribution in cancer cell lines by western blot. Human mesenchymal stem cells were used as control. Protein loading was
detected by Coomassie blue.
See also Figures S3 and S4.

or siRNA 2 transfection for 72 hr (Figure 2H), were able to partially
decrease the CYP2E1 protein in human HepG2 cells, associated
with decreased levels of CT-like activity inhibition by GA. We
further compared the CYP2E1 and CYP1A2 protein level in
some of the cell lines by using human mesenchymal stem cell
(hMSC) as a control. It was found that K562, P388, and HepG2
cancer cells have a higher level of CYP2E1 than other cells
including normal cell (hMSC), while all the cell lines except
hMSC have the similar level of CYP1A2 (Figure 2I).
It has been reported that proteasome inhibition could induce
typical gene expression profile in many cancer cell lines. We
then compared the gene expression profiles between GA and
Vel treatment. We found that GA and Vel yielded not only a similar
gene expression profile but also the similar proteasome inhibition-specific genes (Figure S4; see Extended Results).
Proteasome Inhibition Induced by the Metabolite
Produced by CYP2E1 Is Required for GA’s Cytotoxicity
We next determined whether proteasome inhibition contributes to GA-induced cytotoxicity. We found that inhibition of

CYP2E1 by DDC not only partially rescued GA-induced proteasome inhibition (Figure 2), but also inhibited GA-induced cell
death in P388 and K562 cells (Figures 3A–3G). Exposing
P388 cells to 1 mM of GA for 6 hr in the absence or presence of
DDC resulted in 60% and 20% cell death, respectively (Figures 3A and 3B). Furthermore, GA induced cleavage of PARP
and activation of caspase-9 (but not caspase-8) and caspase3 dose dependently, which was completely inhibited by DDC
(Figures 3C).
The result that inhibition of CYP2E1 suppressed GA-induced
proteasome inhibition (Figure 2) suggests that MT2 has no proteasome-inhibitory activity. Since it is known that CYP1A2 is
the major P450 that is responsible for metabolizing GA to MT2,
one would expect that inhibition of CYP1A2 would lead to no
production of MT2 from GA, which would result in presumably
increased levels of MT1 and consequent proteasome inhibition.
It has been shown that a-naphthoflavone (ANF) at a concentration of 12.5–100 mM is a strong CYP1A2 inhibitor (Liu et al.,
2006). In K562 cells, GA+ANF treatment produced higher levels
of ubiquitinated proteins than each treatment alone (Figure 3D).
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Figure 3. DDC Treatment or CYP2E1
Silencing Partially Reversed while Inhibiting
CYP1A2 Enhanced GA-Induced Cell Death
in Cultured Cancer Cells
(A and B) DDC partially reversed GA-induced cell
death in P388 cells. P388 cells were treated with
GA for 6 hr in the presence of DDC (100 mM), and
cell death was detected by Annexin V and PI
staining with a flow cytometer. Cell death data
were summarized (A) (n = 3), and typical images
were shown (B).
(C) Similar to (B), DDC (100 mM) partially rescued
GA-induced caspase activation and PARP
cleavage by western blotting using specific antibodies as indicated.
(D) a-Naphthoflavone (ANF) enhanced GAinduced caspase activation and PARP cleavage.
K562 cells were treated with GA for 9 hr in the
presence of ANF (25 mM), followed by western
blotting using specific antibodies.
(E and F) ANF enhanced GA-induced cell death by
flow cytometry. Similar to (D), cell death was assayed and summarized (E), and representative
flow images were shown (F).
(G) ANF enhanced GA-induced cell death by PI
staining in living cells. K562 cells were treated
with GA, with or without ANF (25 mM), cell death
was detected by PI staining in living cells.
Representative images at 24 hr were shown. Scale
bar = 50 mm.
(H) Silencing CYP2E1 partially reversed GAinduced cell death while silencing CYP1A2
enhanced GA-induced cell death. HepG2 cells
were transfected with CYP2E1-siRNA and
CYP1A2-siRNA for 48 hr, and then cells were
treated with 0.75 mM of GA for 12 hr, and cell death
was stained with Annexin/PI double staining in situ
and recorded under an inverted fluorescence
microscope.
See also Figures S5, S6, and S7.

ANF alone has no effect on the levels of the proteasome activity
and ubiquitinated proteins. Furthermore, GA+ANF treatment resulted in higher levels of apoptotic cell death than each treatment
alone, as measured by increased PARP cleavage and caspase
cleavage/activation (Figure 3D). ANF also enhanced GA-induced
cell death with propidium iodide (PI) staining in living cells (Figure 3G), and with annexin V/PI double staining by flow cytometry
(Figures 3E and 3F). We have also found that GA-induced proteasome inhibition and cytotoxicity could be partially reversed
by DDC-mediated CYP2E1 inhibition in myeloma cancer cells
(Figure S5; see Extended Results).
To further confirm that the cell death induction by GA is due to
CYP2E1, CYP2E1- and CYP1A2-siRNA were used to silence
CYP2E1 or CYP1A2, respectively. We found that, similar to
proteasome inhibition, silencing CYP2E1 partially rescued GAinduced cell death, whereas silencing CYP1A2 enhanced GAinduced cell death (Figure 3H; Figure S6). These results clearly
showed that GA-induced cytotoxicity relies on its proteasomeinhibitory activity, which is mediated mainly by CYP2E1 and its
metabolite MT1.
We also found that similar to Vel, GA was able to induce endoplasmic reticulum (ER) stress, as measured by increased levels
214 Cell Reports 3, 211–222, January 31, 2013 ª2013 The Authors

of ER-stress-related proteins, CHOP, Bip, PERK, and IRE-1a
(Figure S7). The profiles of other ER-related proteins PDI, Ero11a, and calnexin were also similar between GA and Vel treatment. GA at 0.75 mM yielded the similar effect on ER stress
responses and PARP cleavage to 50 nM dose of Vel in HepG2
cells (Figure S7). These results demonstrated that, similar to
Vel, GA induced the ER stress responses that are associated
with proteasome inhibition-mediated cytotoxicity.
GA Treatment Increases the Survival of P388-Bearing
Mice and Inhibits H22 Tumor Growth and Proteasome
Function In Vivo
We next determined the anticancer effect of GA in vivo by
recording the cumulative survival of mice bearing P388 tumors.
Male KMF mice were inoculated by intraperitoneal (i.p.) injection
with P388 cells and then started i.p. bolus injections of drug
vehicle or 1.5 mg/kg GA for 7 consecutive days, followed by
monitoring survival for the next 60 days (Figure 4A). We found
that all the mice in the vehicle-treated group died within
23 days. In a sharp contrast, only two mice in the GA-treated
group died on day 20 and day 33, respectively, and all the others
survived to the end of the experiment (Figure 4A).

Figure 4. GA Prolongs Survival of Ascities
Bearing P388 Leukemic Cells and Suppresses Solid Tumor Growth In Vivo
(A) GA’s effect on cumulative survival in KMF mice
bearing P388 leukemic cells. Mice bearing P388
cells were treated with i.p. bolus injections of either
vehicle (Veh) or 1.5 mg/kg /day GA for consecutive
7 days. The mice were then kept for 60 days.
(B) GA inhibited proteasome proteolytic function
in vivo. Mice were inoculated with P388 cells for
5 days, and then GA (2 mg/kg) was i.p. injected
once. At 1, 3, 5, 7, and 11 hr after GA injection,
ascities were collected for western blot assay.
(C) GA inhibited tumor growth in vivo. H22 allografts in male KMF mice were treated with either
vehicle or GA at 1.5, 2.0 mg/kg, or 1 mg/kg of Vel
(ten mice each group) for consecutive 7 days. Two
days later after that, the mice were sacrificed;
body weight and the tumor tissues were weighed.
Mean ± SD, *p < 0.0001.
(D) GA inhibited proteasome proteolytic function in
solid tumor in vivo. Mice bearing mouse H22 tumor
were i.p. treated with GA (2 mg/kg) once; at 1, 3, 5,
7, and 11 hr after GA injection, tumor (T) and
muscle tissues (M) were collected for western blot
assay.
(E) GA and Vel only induced PARP cleavage in
tumor tissues in vivo. As in (D), three mice bearing
H22 tumor were i.p. injected with GA (3 mg/kg)
once, and 12 hr later after injection, tumor, muscle,
and liver tissues (L) were collected for detecting
ubiquitinated protein, p27, Bax, PARP, CYP2E1,
and CYP1A2 by western blot. One representative
western image was shown.
(F) GA relative content in mouse tissues. KMF mice
were i.v. injected with GA (8 mg/kg) for 5 or 15 min,
and GA content was detected by high-performance liquid chromatography assay. The peak
area of GA in various tissues was calculated
(average of three repeats).
(G) Accumulation of ubiquitinated proteins in
spleen tissues. Mice were i.p. injected with GA
(2 mg/kg) or Vel (1 mg/kg) as in (D), and ubiquitinated proteins in spleen tissues were detected by
western blot.

To confirm whether GA inhibits the proteasome function
in vivo, dynamic changes of the endogenous proteasome
substrates were assessed. A separate cohort of male KMF
mice was inoculated with P388 cells. Five days later, mice
bearing P388 ascities were i.p. injected with 2 mg/kg of GA. At
different time points, ascities were collected for western blotting
assay. It was found that the proteasome substrate proteins,
including IkBa, p21, p27, p53, and Bax as well as ubiquitinated
proteins all accumulated in a time-dependent manner (Figure 4B), indicative of rapid proteasome inhibition after GA injection. We also tried to measure the CT-like activity in these p388
cancer cells. However, like in other cultured cells, CT-like activity
inhibition could be detected only by cell-based activity assay but
not by in vitro assay using AMC-conjugated proteasome
substrate after GA treatment (data not shown). These results

suggest that the binding of metabolite of GA to proteasome b5
subunit is unstable or transient during protein extraction process, indicating that GA-induced proteasome inhibition is mostly
reversible.
We then determined the antitumor effect of GA in a solid tumor
model in vivo. Male KMF mice were inoculated subcutaneously
(s.c.) in the left armpit with H22 cells, followed by treatment
with GA at 1.5 and 2.0 mg/kg for 7 consecutive days, or Vel at
1 mg/kg every 3 days. Ten days after the inoculation, all the
mice were sacrificed, and the tumors were weighed. As shown
in Figure 4C (upper), tumor weight in the vehicle-treated group
reached 1,900 mg on average, while tumor weight from groups
treated with 1.5 or 2.0 mg/kg GA was 1,400 and 1,100 mg,
respectively, demonstrating 24% and 45% inhibition. At
both doses, GA did not affect the body weight at the end of
Cell Reports 3, 211–222, January 31, 2013 ª2013 The Authors 215

the experiment (Figure 4C, lower). At 1 mg/kg, Vel could inhibit
23% of the growth of H22 allograft close to 1.5 mg/kg GA treatment, and the body weight in Vel-treated mice was similar to the
control mice.
To investigate whether GA could selectively inhibit the proteasome function in solid tumor tissues over normal tissues,
KMF mice bearing H22 tumor were i.p. injected with 2 mg/kg
of GA. At different time points after GA injection, proteasome
substrate proteins p27 and Bax as well as ubiquitinated proteins were found to be accumulated in tumor tissues but not
in muscle tissues (Figure 4D). We further measured and compared the levels of proteasome inhibition, PARP cleavage, and
CYP2E1/CYP1A2 in normal and tumor tissues in mice bearing
H22 tumor after i.p. injection with either GA (3 mg/kg) or Vel
(1 mg/kg) for 12 hr. As shown in Figure 4E, accumulation of proteasome substrate proteins p27 and Bax could be detected in
tumor tissues but not muscle tissues, although ubiquitinated
proteins were found to be increased in both tumors and liver
tissues but not normal muscle tissues (Figure 4E) after GA
and Vel treatment. Furthermore, GA and Vel selectively induced
PARP cleavage only in tumor tissues but not in normal muscle
and liver tissues (Figure 4E), indicating that cancer cells are
more sensitive to proteasome inhibition than normal cells.
Importantly, after treatment of GA and Vel increased expression
mainly in CYP2E1 (and slightly in CYP1A2 protein) was found
in tumors, but not in normal muscle tissues (Figure 4E). The
increased CYP2E1 protein should be able to enhance the effects
of GA. These data demonstrate that GA treatment inhibits H22
solid tumor growth and significantly improves animal survival
in leukemic mice, associated with proteasome inhibition at early
hours.
To further test whether GA is a tissue-specific proteasome
inhibitor in vivo, we detected GA distribution in some of the
relevant normal tissues after GA injection in mice. It was found
that GA could be detected in liver, muscle, and spleen tissues
(Figure 4F), consistent to a previous report (Hao et al., 2007).
GA relative content is 0.69 in rat spleen tissue and 1.15 in
liver tissue after GA intravenous (i.v.) injection for 45 min
(spleen:liver: 60%) (Hao et al., 2007). When tested in mice,
Vel relative content is 3,100 in spleen tissue and 4,500 in
liver tissue after i.v. injection of Vel for 60 min (spleen:liver:
68%) (Adams et al., 1999). We therefore further detected
the proteasome substrate accumulation in spleen tissues after
treatment with GA or Vel. We found that Vel, but not GA, could
dramatically accumulate ubiquitinated proteins (Figure 4G).
Other proteasome substrates like p27 and Bax were not detected (data not shown). Therefore, although low levels of GA
were detectable in spleen, it did not cause proteasome inhibition in this organ, unlike Vel. These results have further demonstrated that GA induces tissue-specific proteasome inhibition,
compared to Vel.
The Reduced Form of GA Fails to Induce Proteasome
Inhibition and Cytotoxicity
To investigate the requirement of the C9-C10 double bond of
GA for proteasome inhibition, C9-C10-disrupted GA (GA), a
reduced form of GA, was chemically synthesized (Figure 5A).
K562 cells were treated with various doses of GA and GA for
216 Cell Reports 3, 211–222, January 31, 2013 ª2013 The Authors

6 hr. Cell-based CT-like activity was detected. It was found
that GA lost its ability to inhibit proteasome activity at a dose
up to 5 mM, and the IC50 of GA for proteasome inhibition is
around 10 mM, 40-fold higher than the IC50 of GA (0.25 mM, Figure 5B). Accordingly, GA dose dependently inhibited cell
viability after 24 or 48 hr treatment in K562 cells, while GA at
<2 mM did not exert any effect on cell viability (Figure 5C);
0.75 mM of GA induced typical cell death, while GA at up to
5 mM did not induce any cell death after 18 hr (Figure 5D).
Further studies in K562 cells found that GA induced PARP
cleavage and ubiquitinated protein accumulation, while GA
did not (Figure 5E). Similar results were found in a myeloma
cell line NCI-H929: at 1 mM or lower doses, GA did not inhibit
CT-like activity, while GA inhibited CT-like activity with an IC50
between 0.250.5 mM (Figure 5F). Consistent to what was
observed in K562 cells, GA at <1 mM did not exert any effect
on cell viability (Figure 5G) and at <5 mM did not affect cell
death either (Figure 5H), while GA at <1 mM dose dependently
inhibited cell viability and induced cell death in NCI-H929 cells.
These results clearly demonstrated that GA-induced cytotoxicity and cell death definitely depend on the existence of
C9-C10 double bond, which is required for its mediated proteasome inhibition.
GA Does Not Decrease Lymphocyte Survival in CYP2E1Deficient Peripheral Blood Cells In Vitro and In Vivo
To further study this importance of CYP2E1 in mediating GAinduced proteasome inhibition and cytotoxicity, the red blood
cells were collected after 24, 48, and 72 hr from mice treated
with either GA (3 mg/kg, i.p.) or Vel (1 mg/kg, i.p.). GA 3 mg/kg
is an effective dose of anticancer therapy (Yi et al., 2008). As expected, only Vel but not GA at the tested doses inhibits the proteasomal CT-like activity in the peripheral blood cells (Figure 6A)
by in vitro peptidase assay. We further detected the peptidase
activity in peripheral blood cells by using cell-based CT-like
activity assay and found that GA did not inhibit CT-like activity
in whole blood cell culture either (Figure 6B). These data demonstrate that GA could inhibit the proteasome function in a cellspecific manner.
Using a whole blood cell culture system, we next compared the effects of GA and Vel on the survival of blood cells.
We first screened the optimal dose of GA and Vel yielding the
similar effect on cell viability in cancer cells. It was found that
in HepG2 cells, 500 nM of GA yielded the similar effect on
cell viability to 50 nM of Vel (data not shown). In the next
peripheral blood experiment, the relative high dose of GA and
Vel was used. As expected, GA at 1 mM did not show any
effects on the survival of blood cells during 7 days of culture
(Figure 6C), while Vel at 0.1 or 0.5 mM dose inhibited white
blood cell and lymphocyte survival as expected (Figure 6D).
These results show that GA led to cell-specific proteasome
inhibition.
One of the most important side effects of chemotherapy is
the inhibition of the hemopoetic system (Richardson et al.,
2005). To further confirm whether therapeutic dose of GA could
affect white blood cell number, the CYP2E1 and CYP1A2 protein
distribution in mouse and human bone marrow cells were
compared with cancer cell lines (Figure 6E). In mouse bone

Figure 5. C9-C10-Disrupted GA Fails to
Induce Proteasome Inhibition, Proliferation
Inhibition, and Cell Death
(A) Chemical structure of GA and GA. C9-C10
double bond was disrupted by adding a piperazine
to C10.
(B) GA failed to inhibit CT-like activity in K562
cells. K562 cells were treated with GA and GA for
6 hr, and CT-like activity in living cells was detected as described above. Mean ± SD (n = 3).
(C) GA failed to inhibit cancer cell viability in K562
cells. K562 cells were treated with GA or GA for
24 or 48 hr, and cell viability was detected by MTS
assay. Mean ± SD (n = 3).
(D) GA lost its ability to induce cell death in K562
cells. K562 cells were treated with GA or GA, PI
was added to the cultured cells after 6 hr treatment, and PI-positive staining was monitored
under an inverted microscope and typical images
at 18 hr time point were shown.
(E) GA failed to induce accumulation of ubiquitinated proteins and PARP cleavage. K562 cells
were treated with various doses of GA or GA for
12 hr, and cells were collected. PARP cleavage
and ubiquitinated proteins were detected by
western blot.
(F) GA failed to inhibit CT-like activity in
NCI-H929 cells. NCI-H929 cells were treated as
in (C), and CT-like activity was detected. Mean ±
SD (n = 3).
(G) GA failed to inhibit cancer cell viability in NCIH929 cancer cells. NCI-H929 cancer cells were
treated as in (C), and cell viability was detected.
Mean ± SD (n = 3).
(H) GA lost its ability to induce cell death in NCIH929 cells. NCI-H929 cells were treated and cell
death was detected as in (D). PI-positive staining
was monitored under an inverted microscope, and
typical images at 6 hr time point were shown.

marrow cells, CYP1A2 was highly, while CYP2E1 was weakly,
expressed compared to the cancer cells (Figure 6E, left). It was
further found that CYP2E1 and CYP1A2 proteins were weakly
expressed in normal human bone marrow cells compared with
the bone marrow cells from leukemic patients (Figure 6E, right).
These results indicated that both normal mouse and human
bone marrow cells weakly express CYP2E1 protein, indicating
an inability for the bone marrow cells to metabolize GA. Second,
Balb/c mice were treated with both GA (4 mg/kg) or Vel (0.5,
1 mg/kg) for 2 weeks, and then peripheral white blood cells
were counted. GA at 4 mg/kg once every other day is effective
anticancer therapy (Guo et al., 2006) and 0.5 mg/kg or 1 mg/kg
dose of Vel is also effective dose of anticancer therapy. GA
was i.v. injected once every other day and Vel was i.v. injected
once every 3 days. It was found that therapeutic dose of GA
(4 mg/kg) did not affect either body weight or peripheral white
blood cells, and Vel (0.5 mg/kg) did not affect these changes
either, while Vel at 1 mg/kg dose did not affect body weight
but dramatically decreased the peripheral white blood cell
number (Figure 6F). These results demonstrated that GA did
not affect cell survival in CYP2E1-deficient cells either in vitro
and in vivo.

GA Induces More Cytotoxicity and Proteasome
Inhibition in Cancer Cells from Leukemic Patients Than
in Human Peripheral Mononuclear Cells
We have confirmed that GA induced cytotoxicity and proteasome inhibition in cancer cell lines and in vivo; next, we further
compared the effects of GA on cytotoxicity and proteasome
inhibition in cancer cells obtained from ten leukemia patients
(five AML-M5, three AML-M2, one ALL, one CLL) and in peripheral mononuclear cells from six normal volunteers. It was found
that GA at all the doses more dramatically decreased cell viability
in leukemic cells than in normal cells while the difference of
Vel-mediated cytotoxicity in leukemic cells and normal cells is
not as high as GA (Figure 7A); GA, similar to Vel, also induced
leukemic cancer cell death (Figures 7B–7D). GA 0.75 mM yielded
the similar effects on cell viability and cell death induction to
100 nM Vel. To determine the levels of proteasome inhibition,
ubiquitinated proteins were detected by western blot. As
shown in Figures 7E and 7F, 50 nM Vel markedly induced
accumulation of ubiquitinated proteins and PARP cleavage in
normal mononuclear cells while GA only slightly induced these
changes compared to Vel; but in leukemic cancer cells, GA at
all the three doses markedly induced both ubiquitinated protein
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Figure 6. GA Does Not Inhibit White Blood
Cell Survival In Vitro and In Vivo
(A) GA did not inhibit proteasome CT-like activity of
red blood cells in vivo. Balb/c mice (n = 3) were i.p.
injected with Vel (1 mg/kg) or GA (3 mg/kg) once,
and red blood cells were collected for CT-like
activity assay after 24, 48, and 72 hr. Veh: vehicle.
Mean ± SD.
(B) GA did not affect CT-like activity in cultured
blood cells. Human peripheral whole blood was
exposed to GA for 6 hr, and CT-like activity was
assayed in living cells by using a cell-based CTlike assay substrate. The relative CT-like activity
was shown (n = 3). 100 nM of Vel was used as
a positive control.
(C) GA did not inhibit lymphocyte survival in vitro.
Human peripheral whole blood was cultured in the
absence or presence of 1 mM GA for 1, 3, 5, and
7 days. The cell count data of polymorphonuclear
(PMN) cells and lymphocytes in DMSO (DM) or
GA-treated group were shown, respectively. Mean
± SD (n = 3).
(D) As in (C), the cells were treated with Vel (0.1,
0.5 mM) instead of GA, and the cell count data were
shown, respectively. Mean ± SD (n = 3).
(E) CYP2E1 and CYP1A2 distribution in mouse and
human bone marrow cells. CYP2E1 and CYP1A2
protein in mouse and human bone marrow cells
(normal control and leukemic sample) were detected by western blot. Cancer cell lines as
indicated were used as controls. CYP2E1 and
CYP1A2 western images in mouse bone marrow
were one representative of the three repeats.
CYP2E1 and CYP1A2 in human bone marrow were
repeated twice, and representative images were
shown.
(F) Therapeutic dose of GA (4 mg/kg) did not
decrease the white blood cell count in vivo. Balb/c
mice were i.v. injected with GA (4 mg/kg) once
every 2 days and Vel (0.5, 1.0 mg/kg) once every
3 days for a total of 14 days. Relative level of white
blood cell count and body weight were summarized. Mean ± SD (n = 3). *p < 0.05, versus vehicle
(Veh) control.

accumulation and PARP cleavage (Figures 7G and 7H). These
results demonstrated that GA, compared to Vel, selectively
induced proteasome inhibition and cytotoxicity in leukemic
cancer cells.
DISCUSSION
GA Is Metabolized to a Potent Proteasome Inhibitor by
P450 Enzyme in the Cell
In the current study, we report that GA inhibits activity of cellular
26S proteasome but not purified 20S proteasome, suggesting
that GA is a proteasome inhibitor prodrug. Furthermore, we
found that GA-induced proteasome inhibition is mediated by
P450 enzyme. The proteasomal subunits b5, b2, and b1 in 20S
218 Cell Reports 3, 211–222, January 31, 2013 ª2013 The Authors

catalytic core are responsible for three
main proteolytic activities of the proteasome, CT-like, trypsin-like, and caspase-like activities, respectively. A threonine residue at the N
terminus (Thr1) of these subunits imparts the catalytic activity
of the proteasome (Groll et al., 2005). The atom Og of Thr1
(Thr1 Og) is activated to be nucleophilic by proton shuttling
from Thr1 Og to the proton acceptor Thr 1 N. Compounds with
electrophilic functional groups are able to react with the nucleophilic Thr 1 Og, causing interference of the proteasomal activity.
Consistently, in the computational modeling study, MT1 but not
GA nor MT2 was docked to the proteasomal b5 subunit that was
suitable for nucleophilic attack by Thr 1 of the b5 subunit (Figure S1). As expected, further studies confirmed that the C9-C10
double bond of GA is a prerequisite for GA-induced proteasome
inhibition (Figure 5). It was also found that GA induced the similar
ER stress responses (Figure S6) and yielded the similar gene

Figure 7. GA-Induced Cytotoxicity and Proteasome Inhibition in Cancer Cells from
Patients with Leukemias
(A) GA dose dependently decreased leukemic cell
viability. Mononuclear cells isolated from either
patients or volunteers were treated with GA and
Vel for 24 hr, and cell viability was detected by
MTS assay. Control group: n = 6; Leukemia group:
n = 9. *p < 0.05, **p < 0.01, versus each dose of
leukemia group.
(B–D) GA induced cell death in leukemic cancer
cells. Leukemia cells were treated by three doses
of GA and two doses of Vel for 24 hr, cells were
labeled with PI and Annexin F-FITC, and the fluorescence was detected with flow cytometry or
observed under a fluorescence microscope. Total
samples from seven leukemia patients were detected for cell death assay. One representative
morphological image is shown in (B) and flow
image is in (C). Cell death data from seven patients
by flow cytometry are shown in (D). Mean ± SD
(n = 7), *p < 0.05, **p < 0.01, compared to the
vehicle control.
(E–H) GA induced more ubiquitinated protein
accumulation and PARP cleavage in leukemia
cancer cells than in normal cells. Mononuclear
cells were incubated with GA and Vel (50 nM) for
15 hr, and ubiquitinated protein and PARP were
detected by western blot. GAPDH was used as
a loading control. A representative western image
from three repeats is shown in (E), and the band
intensities of ubiquitinated proteins (n = 3) are
summarized in (F) in normal mononuclear cells,
while, in leukemia cancer cells, a representative
western image from three repeats is shown in (G),
and the band intensities of ubiquitinated proteins
(n = 3) are summarized in (H). *p < 0.05, **p < 0.01,
versus vehicle control.

expression profile (Figure S4) to the specific proteasome inhibitor Vel. These results confirm that GA indirectly and potentially
targets tumor proteasome in the cell.
Even though the metabolite MT1 could directly inhibit CT-like
activity, we could not completely exclude the possibility for GAinduced metabolite MT1 to interact with the 19S proteasome
mainly for two reasons: (1) MG132 at 0.5 mM and MG262 at
0.25 mM completely inhibit the proteasome CT-like activity, but
these doses of agents and GA could still synergistically accumulate ubiquitinated proteins; (2) the optimal IC50 value of MT1 for
20S proteasome CT-like activity is around 0.5 mM, but the IC50
value in some of the leukemic cells was as low as 0.25 mM, indi-

cating that GA could possibly affect both
20S and 26S proteasome.
We have found that GA’s metabolite
MT1 metabolized by CYP2E1 is responsible for the proteasome inhibition. As
DDC could inhibit both CYP2E1/
CYP2A6 and CYP1A2 activity (Kot and
Daniel, 2009), silencing CYP2E1 only
partially reversed GA-induced proteasome inhibition and GA could still induce
ubiquitinated protein accumulation in the absence of CYP2E1
in normal mononuclear cells (Choudhary et al., 2005). We could
therefore not completely exclude other P450 enzymes besides
CYP2E1 involved in the metabolism of GA to MT1.
GA at Therapeutic Dose Induces Cytotoxicity via
Proteasome Inhibition
We then determined whether proteasome inhibition is required for GA’s cytotoxicity and anticancer activity. We found
that blocking the CYP1A2 pathway enhanced, while blocking
CYP2E1 pathway reversed GA-induced proteasome inhibition
and cell death. Importantly the IC50 of GA for cancer cellular
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proteasome activity is 0.25–0.75 mM, similar to its IC50 (0.5–
1.5 mM) for cytotoxicity (Zhang et al., 2004). These data imply
that proteasome inhibition is a prerequisite for GA-induced cell
proliferation arrest and cell death. An early study reported that
transferrin receptor is an important target of GA and the lowest
IC50 for inhibiting transferrin receptor is >2 mM (Pandey et al.,
2007), but the IC50 of GA’s cytotoxicity is <1 mM, mostly
0.5 mM in cancer cell lines (Zhang et al., 2004). Another reported
important target is related to angiogenesis (Yi et al., 2008), but
based on our data, leukemic cancer cells were more sensitive
to GA compared to other nonleukemic cells, and GA significantly
improved mouse survival bearing P388 ascities in which no
angiogenesis exists.
Even though CYP2E1 inhibition by either chemical inhibitor
DDC or siRNA could partially reverse GA-induced proteasome
inhibition and cytotoxicity, we still could not completely exclude
the off-target effect of GA on cell viability and cell death. Since
the C9-C10 double bond of GA is responsible for GA-induced
proteasome inhibition, we therefore synthesized a reduced
form of GA by disrupting the C9-C10 double bond of GA. After
disruption of this double bond, as expected, GA lost its ability
to inhibit proteasome activity within 5 mM dose. Accordingly,
GA at <5 mM did not induce any cell death, indicating that proteasome inhibition is required for GA-induced cell death. The
most important is that both in NCI-H929 and K562 cancer cells,
GA at <1 or 2 mM doses did not affect either the cell viability or
cell proliferation, indicating that proteasome inhibition determines GA-induced cell growth arrest. Since GA at < 1 mM has
almost completely inhibited cell viability, we suggest that GAinduced decreased cell viability and cell death rely on proteasome inhibition. However, further studies are needed in order
to confirm whether there is any off-target mechanism involved
in GA-mediated effect.
GA Is a Cell-Specific Proteasome Inhibitor Compared
to Vel
Proteasome inhibition has been used for cancer therapy and Vel
has been approved by US Food and Drug Administration for
treating multiple myeloma (Richardson et al., 2005; Adams,
2004). As the proteasome exists in all the cells, specific proteasome inhibitors would definitely inhibit the proteasome function
to some extent. Therefore, one important approach is to discover new proteasome inhibitors with efficient antitumor effects
and cell-specific proteasome inhibition to decrease the toxic
side effects. Since the expression of the p450 system in red
blood cells and other peripheral blood cells is relatively low or
deficient (Choudhary et al., 2005), we hypothesize that GA may
not affect the proteasome activity in these cells in vitro and
in vivo. GA indeed did not dramatically affect these proteasome
activities in low CYP2E1-expressing whole blood cells. However
in purified human peripheral mononuclear cells, GA at a higher
dose could still induce accumulation of ubiquitinated proteins
to some extent, implying the possible existence of P450 enzyme
or other enzymes metabolizing GA in human peripheral mononuclear cells. Since proteasome is the specific molecular target of
GA, next we compared the effects of GA and Vel on lymphocyte
in vitro and in vivo. At their efficient doses, GA did not dramatically affect lymphocyte number both in vitro and in vivo consis220 Cell Reports 3, 211–222, January 31, 2013 ª2013 The Authors

tent to previous report (Guo et al., 2003), while a high dose of
Vel dramatically inhibits lymphocyte number in vitro and in vivo.
Consistent to the proteasome inhibition, GA could also induce
cytotoxicity to some extent in human peripheral mononuclear
cells but much lower than in leukemic cancer cells. Based
on these results, we conclude that the specific distribution of
CYP2E1 or other related P450 enzyme plays an important role
in determining GA-induced proteasome inhibition and cytotoxicity. It was further found that Vel but not GA could induce proteasome inhibition in spleen tissues in vivo. These results confirm
that GA induces cell-specific proteasome inhibition compared
to Vel.
Cell-specific proteasome inhibition would be significant in
designing a novel strategy to overcome multiple proteasome
malfunction-related diseases. In clinical cancer chemotherapy
including Vel therapy, one of the important side effects is
the toxic effect on immune system and hemopoietic system (Richardson et al., 2005; Adams, 2004). First, as expected, CYP2E1
is weakly or even not expressed in mature peripheral lymphocytes and hemopoietic cells (Choudhary et al., 2005). Since
these cells lack of CYP2E1 to metabolize GA, it is possible that
GA is less toxic on lymphocytes and the hemopoietic system
(Guo et al., 2003). Second, all the 60 NCI cancer cell lines displayed high P450 activity including CYP2E1 activity and in six
human myeloblastic and lymphoid cell lines (Nagai et al., 2002;
Yu et al., 2001), and our results also found that most of the
cancer cells have a relatively higher level of CYP2E1 compared
with the normal human MSC. Also, the normal tissues express
low levels of CYP2E1 except the liver and the kidney (Choudhary
et al., 2005), so GA should be an anticancer candidate that is less
toxic to normal tissues. Our results further confirm that CYP2E1
is very weakly expressed in bone marrow blood cells from
normal humans but highly expressed in bone marrow cells
from leukemic patients. Even though therapeutic dose of GA
does not dramatically affect the liver and the kidney (Guo et al.,
2006), consistent to the CYP2E1 distribution, a toxic dose of
GA could affect the function of the liver and the kidney (Qi
et al., 2008). Finally, compared with traditional proteasome
inhibitors, GA-induced proteasome inhibition is cell- or organ
specific, as a specific proteasome inhibitor it will potentially be
used in different organ dysfunction. In summary, we have identified GA as a potent proteasome inhibitor and GA-induced cellspecific proteasome inhibition should be of great importance in
the future clinical trials.
EXPERIMENTAL PROCEDURES
Peptidase Activity Assay
In vitro CT-like peptidase assay was performed as described with the
synthetic fluorogenic peptide Suc-LLVY-AMC purchased from Calbiochem.
Cell-based peptidase assay was performed as reported (Huang et al.,
2011b). Briefly, cells (4,000/well) were treated with an indicated agents at
37 C for 6 hr, followed by incubation with the Promega Proteasome-Glo
Cell-Based Assay Reagent (Promega Bioscience, Madison, WI) for 15 min.
Luminescence was detected with luminescence microplate reader (Varioskan
Flash 3001, Thermo, USA).
Models of H22 Allografts and P388 Ascities
All animal protocols used were approved by the Institutional Animal Care and
Use Committee of Guangzhou Medical College. The mice were obtained from

Guangdong Laboratory Animal Monitoring Institute (SCXK2008-2002). P388
ascities mouse model was performed as reported (Yang et al., 2009). After
24 hr i.p. inoculation, male KMF mice were treated with i.p. bolus injections
of the drug vehicle (10% DMSO, 15% ethanol, and 75% PBS) or GA
(1.5 mg/kg) for 7 consecutive days, and kept for additional 60 days to monitor
survival daily.
H22 allograft model was performed as described (Yang et al., 2009). Murine
H22 cells (10 3 106) suspended in 0.2 ml of RPMI 1640 medium were inoculated s.c. in the left armpit of each mouse. After 24 hr of inoculation, mice
(ten mice per group) were treated with either vehicle (10% DMSO, 30% Cremophor, and 60% PBS) or GA (1.5, or 2.0 mg/kg of body weight) via daily
i.p. injection for 7 consecutive days, or Vel (1 mg/kg) every 3 days. Two days
after the treatment, the mice were sacrificed, and the tumor tissues were
weighed.
DNA Microarray Assay and Analysis
HepG2 cells were treated with GA or Vel for 9 hr, and then cells were extracted
with TRIzol agents. DNA microarray was performed by Kangchen biotech
company (Shanghai) in compliance to MIAME guidelines (for more details,
refer to the Extended Experimental Procedures).
Statistical Methods
Mean ± SD are presented where applicable. Unpaired Student’s t test or oneway ANOVA is used for determining statistic probabilities. p value <0.05 is
considered significant.
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